Effects of Intracerebroventricular Administration of Neuropeptide Y on Metabolic Gene Expression and Energy Metabolism in Male Rats.
Neuropeptide Y (NPY) is an important neurotransmitter in the control of energy metabolism. Several studies have shown that obesity is associated with increased levels of NPY in the hypothalamus. We hypothesized that the central release of NPY has coordinated and integrated effects on energy metabolism in different tissues, resulting in increased energy storage and decreased energy expenditure (EE). We first investigated the acute effects of an intracerebroventricular (ICV) infusion of NPY on gene expression in liver, brown adipose tissue, soleus muscle, and sc and epididymal white adipose tissue (WAT). We found increased expression of genes involved in gluconeogenesis and triglyceride secretion in the liver already 2-hour after the start of the NPY administration. In brown adipose tissue, the expression of thermogenic genes was decreased. In sc WAT, the expression of genes involved in lipogenesis was increased, whereas in soleus muscle, the expression of lipolytic genes was decreased after ICV NPY. These findings indicate that the ICV infusion of NPY acutely and simultaneously increases lipogenesis and decreases lipolysis in different tissues. Subsequently, we investigated the acute effects of ICV NPY on locomotor activity, respiratory exchange ratio, EE, and body temperature. The ICV infusion of NPY increased locomotor activity, body temperature, and EE as well as respiratory exchange ratio. Together, these results show that an acutely increased central availability of NPY results in a shift of metabolism towards lipid storage and an increased use of carbohydrates, while at the same time increasing activity, EE, and body temperature.
Hypothalamic Integration Mechanisms (Y.S., A.K.), Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands; and Department of Endocrinology and Metabolism (E.Fo.,E.Fl., A.K.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Yan
Y
Su
Hypothalamic Integration Mechanisms (Y.S., A.K.), Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands; and Department of Endocrinology and Metabolism (E.Fo.,E.Fl., A.K.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Ewout
E
Foppen
Hypothalamic Integration Mechanisms (Y.S., A.K.), Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands; and Department of Endocrinology and Metabolism (E.Fo.,E.Fl., A.K.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Eric
E
Fliers
Hypothalamic Integration Mechanisms (Y.S., A.K.), Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands; and Department of Endocrinology and Metabolism (E.Fo.,E.Fl., A.K.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Andries
A
Kalsbeek
D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D004734:Energy Metabolism / Q000187:drug effects* / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007276:Injections, Intraventricular; D007328:Insulin / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009478:Neuropeptide Y / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D007328:Insulin; D009478:Neuropeptide Y; D003345:Corticosterone